Twist Biosciences, a biotech specializing in DNA synthesis, has revealed details of its new, state-of-the-art facilities the company says may drive competitive pricing in nucleic acid biologics. The facility, set in Oregon, US, is equipped with four DNA manufacturing devices and has room to grow, up to a total of 12. In addition, the upgrades will help speed production in other ways.
According to Tyler Patchen, “Management also told SVB that its products can spend up to 50% of their time in storage, but the new factory will address this by “consolidating instrumentation and streamlining in the process.” This will be crucial if Twist plans to launch its “Fast Gene” product in 2023, which is going to accelerate delivery time for its existing products.”
To read more, click here.
(Source: Endpoints News, November 30th, 2022)
